BioSpectra, Inc. has launched contract manufacturing services for pharma and biopharma products from its new FDA-registered facility in Bangor, PA. BioSpectra provides custom cGMP purifications, acidifications, acid/base reactions, custom formulations and particle manipulation, along with documented regulatory support.
 
“BioSpectra is proud of its customer-focused, custom manufacturing capabilities which provide a unique combination of industry-leading quality – from process chemistry through finished end product,” said Richard Mutchler, president of BioSpectra. “Our clients rest assured knowing they are working with a partner who offers written, declared end-use statements detailing the product is designed, engineered, validated and manufactured solely for the purpose it’s being used. Therefore, we confirm in advance the strict controls with which BioSpectra governs its equipment, processes and products.”